Methylprednisolone Plus Low-Dose Methotrexate for Bullous Pemphigoid—A Single Center Retrospective Analysis

Monomodal systemic glucocorticoids remain the mainstay of treatment for bullous pemphigoid (BP). In this retrospective, single-arm study, we evaluated the feasibility (efficacy and tolerability) of the combination of methylprednisolone and low-dose (up to 12.5 mg/week) methotrexate (MP + MTX) for BP...

Descripción completa

Detalles Bibliográficos
Autores principales: Gravani, Agoritsa, Gaitanis, Georgios, Spyridonos, Panagiota, Alexis, Ioannis, Tigas, Stelios, Bassukas, Ioannis D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181025/
https://www.ncbi.nlm.nih.gov/pubmed/35683576
http://dx.doi.org/10.3390/jcm11113193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181025/
https://www.ncbi.nlm.nih.gov/pubmed/35683576
http://dx.doi.org/10.3390/jcm11113193

Ejemplares similares